ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Instituto Valenciano de Oncologia
Valencia, EspañaPublications en collaboration avec des chercheurs de Instituto Valenciano de Oncologia (17)
2022
-
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA
Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800
2021
-
Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project
European Journal of Surgical Oncology, Vol. 47, Núm. 2, pp. 276-284
2017
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2015
-
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial
The Lancet Oncology, Vol. 16, Núm. 8, pp. 928-936
2013
-
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2010
-
Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel
Journal of the National Cancer Institute, Vol. 102, Núm. 20, pp. 1547-1556
2007
-
Treatment guidelines in ovarian cancer
Clinical and Translational Oncology, Vol. 9, Núm. 5, pp. 308-316
2003
-
Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
Annals of Oncology, Vol. 14, Núm. 3, pp. 441-448
-
Irinotecan (CPT-11) in Metastatic Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU): A Phase II Study
Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, Núm. 8, pp. 639-643
2001
-
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: An EORTC gynaecological cancer cooperative group study
Gynecologic Oncology, Vol. 81, Núm. 3, pp. 348-354
2000
-
Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer
Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158
1999
-
UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients
ONCOLOGY, Vol. 13, Núm. 7 SUPPL., pp. 35-40
1996
-
Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial
Annals of Oncology, Vol. 7, Núm. 6, pp. 581-585
1995
-
A phase II trial of weekly high dose continuous infusion 5‐fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
Cancer, Vol. 76, Núm. 4, pp. 559-563